Autologous CAR-T manufacturing is highly personalized, creating challenges across cost, efficiency, patient safety, scalability, and turnaround time. Thermo Fisher Scientific is expanding its cell therapy manufacturing portfolio through three connected layers: flexible automated Gibco CTS instruments, GMP-ready reagents, and an open digital platform for secure system integration. Together, these solutions help cell therapy developers address manufacturing barriers and streamline workflows from process development through commercial production.